A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : O6-BG / O6-benzylguanine

[Related PubMed/MEDLINE]
Total Number of Papers: 70
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   O6-BG  (>> Co-occurring Abbreviation)
Long Form:   O6-benzylguanine
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 Development and biological evaluation of AzoBGNU: A novel hypoxia-activated DNA crosslinking prodrug with AGT-inhibitory activity. CENUs
2021 Single-dose MGTA-145/plerixafor leads to efficient mobilization and in vivo transduction of HSCs with thalassemia correction in mice. G-CSF, HSC
2020 O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy. MGMT, MSP, O6-BTG
2020 Site-Directed Mutagenesis at the Molybdenum Pterin Cofactor Site of the Human Aldehyde Oxidase: Interrogating the Kinetic Differences Between Human and Cynomolgus Monkey. AO, hAO, mAO
2020 Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. GBM, MGMT, oHSV, TMZ
2020 The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide + irinotecan against models of high-risk neuroblastoma. MGMT, TLDA, TMZ
2019 Factorial Design as a Tool for the Optimization of PLGA Nanoparticles for the Co-Delivery of Temozolomide and O6-Benzylguanine. EE, FFD, GBM, NPs, PLGA, TMZ
2019 Novel multi-drugs incorporating hybrid-structured nanofibers enhance alkylating agent activity in malignant gliomas. HSNM, MGMT, MGs, TMZ
2019 Reductive Activity and Mechanism of Hypoxia- Targeted AGT Inhibitors: An Experimental and Theoretical Investigation. 2-nitro-6-benzyloxypurine, DFT
10  2018 Biodegradable hybrid-structured nanofibrous membrane supported chemoprotective gene therapy enhances chemotherapy tolerance and efficacy in malignant glioma rats. HSNMs, MG, TMZ
11  2018 Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors. HSC, TMZ
12  2018 Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O6-methylguanine-DNA methyltransferase with a double arm hybrid molecule. EGFR, MGMT, TMZ
13  2018 PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma. HR, MAO-B, MGMT, MMR, NER, NHEJ, TMZ
14  2018 Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo. MGMT, MMR, TMZ
15  2017 Synthesis and Antitumor Activity Evaluation of a Novel Combi-nitrosourea Prodrug: BGCNU. BGCNU, CENUs, ICLs
16  2017 Synthesis of PET probe O6-[(3-[11C]methyl)benzyl]guanine by Pd0-mediated rapid C-[11C]methylation toward imaging DNA repair protein O6-methylguanine-DNA methyltransferase in glioblastoma. MGMT
17  2017 Uptake of glucose-conjugated MGMT inhibitors in cancer cells: role of flippases and type IV P-type ATPases. MGMT, O6BTG
18  2015 Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells. CSCs, GBM, Ihh, MGMT, SP, TMZ
19  2014 Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. HSCs, OS, PFS, TMZ
20  2013 Nano-p-n junction heterostructure TiO2 nanobelts for the electrochemical detection of anticancer drug and biointeractions with cancer cells. ---
21  2012 In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model. GBM, HSCs, TMZ
22  2011 A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. SD, TMZ
23  2010 Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. BCNU
24  2009 Effect of O6-chloroethylguanine DNA lesions on the kinetics and mechanism of micronucleus induction in vivo. BCNU, DMSO, MNPCE, O6-ChlEt-G
25  2009 Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. CSF, OS
26  2008 Degradation of BRCA2 in alkyltransferase-mediated DNA repair and its clinical implications. ---
27  2007 Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. 5-FU, MGMT
28  2007 O6-benzylguanine and BCNU in multiple myeloma: a phase II trial. MGMT
29  2007 Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. DLT
30  2007 Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression. BCNU, HSCs
31  2006 A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. MGMT
32  2006 Fluorophores for live cell imaging of AGT fusion proteins across the visible spectrum. BGDEAC, CP-TMR, ECFP, EGFP, mRFP
33  2006 Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. ---
34  2006 Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. ---
35  2005 Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. DLT, TMZ
36  2005 Role of O6-methylguanine-DNA methyltransferase and effect of O6-benzylguanine on the anti-tumor activity of cis-diaminedichloroplatinum(II) in oral cancer cell lines. MGMT
37  2005 Synthesis and preliminary biological evaluation of O6-[4-(2-[18F]fluoroethoxymethyl)benzyl]guanine as a novel potential PET probe for the DNA repair protein O6-alkylguanine-DNA alkyltransferase in cancer chemotherapy. O6-FBG, O6-FEMBG, 1, PET
38  2004 Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. OBR
39  2004 Interstitial infusion of carmustine in the rat brain stem with systemic administration of O6-benzylguanine. ---
40  2003 Irinotecan: promising activity in the treatment of malignant glioma. ---
41  2002 Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma. BCNU, BR, GST, ICLs, OBR, OBR, OBR
42  2002 O6-benzylguanine-mediated enhancement of chemotherapy. AGT, BCNU
43  2002 Toxicity of intracranial and intraperitoneal O6-benzyl guanine in combination with BCNU delivered locally in a mouse model. BCNU, i.p, IC, MTD
44  2001 Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter. BCNU, CENUs, EMT, MGMT, RT-PCR, SarCNU
45  2001 Inactivation of O(6)-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors. O6BTG
46  2000 O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. ---
47  2000 O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials. BCNU
48  2000 Potentiation of BCNU anticancer activity by O6-benzylguanine: a study in vitro and in vivo. BCNU, O6-AGT
49  1999 Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. 4-HC, 4-HCR
50  1999 Tetrazepinones are equally cytotoxic to Mer+ and Mer- human tumor cell lines. BCNU, MGMT
51  1998 Effects of O6-benzylguanine on growth and differentiation of P19 embryonic carcinoma cells treated with alkylating agents. AT, EMS, ENU, MMS, MNU, RA
52  1998 Heterogeneity of O6-alkylguanine-DNA-alkyltransferase measured by flow cytometric analysis in blood and bone marrow mononuclear cells. CHO, FACS, PBMCs
53  1998 Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. 8-oxo-O6BG, CSF
54  1998 Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. AGT, BCNU, HPLC
55  1998 Simultaneous determination of O6-benzylguanine and 8-oxo-O6-benzylguanine in human plasma by reversed-phase high-performance liquid chromatography. 8-oxo-O6BG
56  1997 Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. ---
57  1997 Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. AGAT, i.a, i.p, i.v
58  1997 Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents. MGMT, MNU
59  1996 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. 3-AB, BCNU, PARP
60  1996 Differential sensitivity of human and mouse alkyltransferase to O6-benzylguanine using a transgenic model. CHO
61  1996 O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. BCNU, s.c
62  1996 Potentiation of testicular cytotoxicity by the alkyltransferase inhibitor O6 benzylguanine and the 5-fluorouracil/N-(2-chloroethyl)-N-nitrosourea molecular combination, B.4152. AGT
63  1996 Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. MGMT
64  1995 Contribution of O6-methylguanine-DNA methyltransferase to monofunctional alkylating-agent resistance in human brain tumor-derived cell lines. ENU, MGMT, MNNG
65  1995 Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines. BCNU, MGMT
66  1995 Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. CSF, MGMT
67  1995 Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity. ATase, BCNU, CENUs
68  1994 Combined depletion of O6-alkylguanine-DNA alkyltransferase and glutathione to modulate nitrosourea resistance in breast cancer. BCNU, CNUs, L-BSO, O6MG
69  1993 Chemosensitisation of alkylating agents by pentoxifylline, O6-benzylguanine and ethacrynic acid in haematological malignancies. AML, BCNU, CLL, EA, GST, MAF, PTX, RM
70  1993 The role of the carboxyl-terminal tail in human O6-methylguanine DNA methyltransferase substrate specificity and temperature sensitivity. MGMT, O6MG, PCHRV